本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Vir Biotechnology, Inc.

10.87
+0.96009.69%
成交量:171.14萬
成交額:1,860.73萬
市值:18.33億
市盈率:-6.40
高:11.28
開:10.03
低:9.97
收:9.91
52周最高:11.66
52周最低:4.36
股本:1.69億
流通股本:1.30億
量比:2.01
換手率:1.32%
股息:- -
股息率:- -
每股收益(TTM):-1.6972
每股收益(LYR):-3.1619
淨資產收益率:-26.08%
總資產收益率:-14.51%
市淨率:1.87
市盈率(LYR):-3.44

資料載入中...

2026/03/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/04

重要事件披露

Form 8-K - Current report
2026/03/03

關聯方擬減持公告

Form 144 | VIR BIO高管 Vicki Lee Sato 擬減持88000股,總價約80萬美元
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/26

重要事件披露

Form 8-K - Current report
2026/02/25

關聯方擬減持公告

Form 144 | Vir Biotechnology 股東 SVF Endurance (Cayman) Limited 擬減持40萬股,總價約380萬美元
2026/02/25

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/25

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/23

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/02/23

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/02/23

重要事件披露

Form 8-K - Current report
2026/02/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities